Allan CJ, Higashiura K, Martin M, Morinelli TA, Kurtz DT, Geoffroy O, Meier GP, Gettys TW, and Halushka PV (1996) Characterization of the cloned HEL cell thromboxane A2 receptor: evidence that the affinity state can be altered by G alpha 13 and G alpha q. J Pharmacol Exp Ther 277:1132-1139.
Becker KP, Ullian M, and Halushka PV (1998) Cloning and characterization of an endogenous COS-7 cell thromboxane A2 receptor. Biochim Biophys Acta 1403: 109-114.
Born GV and Cross MJ (1963) The aggregation of blood platelets. J Physiol (Lond) 168:178-195.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, and Cohen RA (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728.
Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, and FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (Wash DC) 296:539-541.
Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F, and Patrono C (2000) Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102:1007-1013.
Coleman RA, Humphrey PP, Kennedy I, Levy GP, and Lumley P (1981) Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol 73:773-778.
Coleman RA, Smith WL, and Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229.
Dogné JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, Casini A, Masereel B, Ruan KH, Pirotte B, et al. (2004a) New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 11:1223-1241.
Dogné JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, and Massereel B (2000) Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukotrienes Essent Fatty Acids 62:311-317.
Dogné JM, Hanson J, de Leval X, Kolh P, Tchana-Sato V, de Leval L, Rolin S, Ghuysen A, Segers P, Lambermont B, et al. (2004b) Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methylphenylamino)-5- nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 309:498-505.
Dogné JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F, Delarge J, and Masereel B (2001) Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 53:669-680.
Ghuysen A, Lambermont B, Dogné JM, Kolh P, Tchana-Sato V, Morimont P, Magis D, Hanson J, Segers P, and D'Orio V (2004) Effect of BM-573 [N-terbutyl-N′-[2-(4′-methylphenylamino)-5-nitro-benzenesulfonyl] urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther 310:964-972.
Gonnan RR, Johnson RA, Spilman CH, and Aiken JW (1983) Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3′-pyridinylmethyl) benzofuran-2-carboxylate. Prostaglandins 26:325-342.
Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, and Vermylen J (1987) Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Investig 80:1435-1445.
Grynkiewicz G, Poenie M, and Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 260:3440-3450.
Habib A, FitzGerald GA, and Maclouf J (1999) Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem 274:2645-2651.
Hamberg M, Svensson J, and Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998.
Harris DN, Asaad MM, Phillips MB, Goldenberg HJ, and Antonaccio MJ (1979) Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res 5:125-134.
Hayes JS, Lawler OA, Walsh MT, and Kinsella BT (1999) The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. J Biol Chem 274:23707-23718.
Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, and Narumiya S (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (Lond) 349:617-620.
Kinsella BT, O'Mahony DJ, and Fitzgerald GA (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281:957-964.
Kurz KD, Main BW, and Sandusky GE (1990) Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 60:269-280.
Lambermont B, Kolh P, Ghuysen A, Segers P, Dogné JM, Tchana-Sato V, Morimont P, Benoit P, Gerard P, Masereel B, et al. (2004) Effect of a novel thromboxane A2 inhibitor on right ventricular-arterial coupling in endotoxic shock. Shock 21:45-51.
Mais DE, DeHoll D, Sightler H, and Halushka PV (1988) Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels. Eur J Pharmacol 148:309-315.
Mais DE, Saussy DL Jr, Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N, and Halushka PV (1985) Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J Pharmacol Exp Ther 233:418-424.
Miggin SM and Kinsella BT (1998) Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochim Biophys Acta 1425:543-559.
Mohrland JS, Vander Lugt JT, and Lakings DB (1990) Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects. Eur J Clin Pharmacol 38:485-488.
Moncada S and Vane JR (1978) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2 and prostacyclin. Pharmacol Rev 30:293-331.
Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1:1710-1713.
Qiao N, Reynaud D, Demin P, Halushka PV, and Pace-Asciak CR (2003) The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected COS-7 cells. J Pharmacol Exp Ther 307:1142-1147.
Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, and Ware JA (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 269:19256-19261.
Reynaud D, Hinek A, and Pace-Asciak CR (2002) The hepoxilin analog PBT-3 inhibits heparin-activated platelet aggregation evoked by ADP. FEBS Lett 515: 58-60.
Rolin S, Dogné JM, Michaux C, Delarge J, and Masereel B (2001) Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukotrienes Essent Fatty Acids 65:67-72.
Saussy DL Jr, Mais DE, Knapp DR, and Halushka PV (1985) Thromboxane A2 and prostaglandin endoperoxide receptors in platelets and vascular smooth muscle. Circulation 72:1202-1207.
Soyka R, Guth BD, Weisenberger HM, Luger P, and Muller TH (1999) Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J Med Chem 42:1235-1249.
Stegmeier K, Pill J, Muller-Beckmann B, Schmidt FH, Witte EC, Wolff HP, and Patscheke H (1984) The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb Res 35:379-395.
Takahara K, Murray R, FitzGerald GA, and Fitzgerald DJ (1990) The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 265:6836-6844.
Walsh MT, Foley JF, and Kinsella BT (1998) Characterization of the role of N-linked glycosylation on the cell signaling and expression of the human thromboxane A2 receptor alpha and beta isoforms. J Pharmacol Exp Ther 286:1026-1036.
Walsh MT, Foley JF, and Kinsella BT (2000) The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J Biol Chem 275:20412-20423.
